New insights into the pathophysiology of irritable bowel syndrome: Implications for future treatments

被引：32
作者：
Crowell M.D. [1 ]
Harris L. [1 ]
Jones M.P. [1 ]
Chang L. [1 ]
机构：
[1] Division of Gastroenterology and Hepatology, Mayo Clinic Scottsdale, Scottsdale, AZ 85259
来源：
Current Gastroenterology Reports | 2005年 / 7卷 / 4期
关键词：
Irritable Bowel Syndrome; Functional Dyspepsia; Irritable Bowel Syndrome Patient; Tegaserod; Acute Tryptophan Depletion;
D O I：
10.1007/s11894-005-0019-8
中图分类号：
学科分类号：
摘要：
Irritable bowel syndrome (IBS) is a multifactorial disorder characterized by abdominal pain and altered bowel habits. Chronic symptoms may occur due to changes in gastrointestinal motor function, enhanced perception of gut stimuli, and psychosocial factors. Recent data suggest that abnormal processing of afferent signals occurs in IBS patients. A newly recognized causative factor in a subset of IBS patients is postinfectious IBS. Altered transport of intestinal gas and bowel distention may contribute to abdominal discomfort, pain, and bloating. Changes in gut microflora have also been reported, but data remain scant. Advances have been made in our understanding of serotonin signaling and metabolism in IBS patients, in part due to the introduction of specific receptor agonists and antagonists. Finally, exciting data are emerging on genetic alterations that may contribute to the pathophysiology and treatment of IBS. Increasingly novel mechanisms are being identified that should aid in better understanding of the complex pathophysiology of IBS and developing new therapies. Copyright © 2005 by Current Science Inc.
引用
收藏
页码：272 / 279
页数：7
相关论文
共 74 条
[1]  
Mertz H., Naliboff B., Munakata J., Et al., Altered rectal perception is a biological marker of patients with irritable bowel syndrome, Gastroenterology, 109, pp. 40-52, (1995)
[2]  
Delvaux M., Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome, Gut, 51, SUPPL. 1, (2002)
[3]  
Whitehead W.E., Palsson O.S., Is rectal pain sensitivity a biological marker for irritable bowel syndrome: Psychological influences on pain perception, Gastroenterology, 115, pp. 1263-1271, (1998)
[4]  
Drossman D.A., Review article: An integrated approach to the irritable bowel syndrome, Aliment. Pharmacol. Ther., 13, SUPPL. 2, pp. 3-14, (1999)
[5]  
Camilleri M., Talley N.J., Pathophysiology as a basis for understanding symptom complexes and therapeutic targets, Neurogastroenterol. Motil., 16, pp. 135-142, (2004)
[6]  
Viramontes B.E., Camilleri M., McKinzie S., Et al., Gender related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome, Am. J. Gastroenterol., 92, pp. 2671-2676, (2001)
[7]  
Prather C.M., Camilleri M., Zinsmeister A.R., Et al., Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome, Gastroenterology, 96, pp. 455-459, (2000)
[8]  
Cremonini F., Delgado-Aros S., Camilleri M., Efficacy of alosetron in irritable bowel syndrome: A meta-analysis of randomized control trials, Neurogastroenterol. Motil., 15, pp. 79-86, (2003)
[9]  
Novick J., Miner P., Krause R., Et al., A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome, Aliment. Pharmacol. Ther., 16, pp. 1877-1888, (2002)
[10]  
Kellow J., Lee O.Y., Chang F.Y., Et al., An Asia-Pacific, double blind, placebo controlled, randomized study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome, Gut, 52, pp. 671-676, (2003)
12345678